Breast Cancer

In this randomized trial, adding a pictorial COPE photo guide to standard verbal counseling for breast cancer patients receiving adjuvant RT led to the only statistically significant improvement in post-treatment skin change scores, with modest non-significant trends toward reduced anxiety.

Sherry Shen, MD, explained the compounding factors behind weight gain during breast cancer care and why managing cardiometabolic health is vital for survival.

This narrative review summarizes existing literature and clinical trial data on metastasis-directed and locoregional therapy for oligometastatic and oligoprogressive metastatic breast cancer, highlighting special scenarios where MDT may improve outcomes.

A streamlined clinical research team workflow at a Columbia University–affiliated community hospital achieved 5% to 8% annual trial enrollment, surpassing the Commission on Cancer benchmark and earning a National Cancer Institute Silver Award.

Experts discussed the integration of GLP-1 agonists and lifestyle interventions to mitigate obesity-related cancer risks and improve long-term survival.

Qualitative interviews with 43 patients on capivasertib plus fulvestrant found the 4-on/3-off dosing schedule broadly acceptable, while identifying gaps in hyperglycemia recognition and willingness to use supportive medications.

This 13-case pictorial review from the University of Rochester Medical Center illustrates the variable mammography, ultrasound, and MRI presentations of pleomorphic invasive lobular carcinoma to support timely interdisciplinary diagnosis.

A panel of exerts discussed key takeaways happening in the field of HER2+ metastatic breast cancer.

This pictorial case series of 5 intramammary spindle-cell lesions demonstrates characteristics that support confident benign diagnosis after biopsy without surgical excision.

This prospective study found that diffuse optical spectroscopy identified elevated collagen as a significant biomarker for breast cancer malignancy, supporting further investigation of DOS as a noninvasive complement to biopsy.

A panel of exerts discussed key takeaways happening in the field of HR+/HER2– breast cancer.

Using spatial proteomics and nanomechanical profiling across two clinical cohorts, investigators identified hypoxia-driven epithelial-to-mesenchymal transition as a biological signature linking aggressive biomechanical phenotypes to poor breast cancer outcomes.

A theory-driven paper planner combined with a digital AI companion demonstrated high acceptability and improved treatment confidence among patients with metastatic TNBC initiating ADC therapy.

In this Florida Cancer Data System mediation analysis, racialized economic segregation and insurance disadvantage explained 29% of the racial disparity in advanced breast cancer stage at diagnosis between Black and White women.

In this Florida Cancer Data System analysis, structural racism and health insurance disadvantage together mediated nearly 8% of the racial disparity in TNBC between Black and White women.

This retrospective claims analysis found neutropenia carried substantial economic burden in HR+/HER2– and triple-negative mBC, with the highest neutropenia-related costs seen during sacituzumab govitecan regimens.

This review of monarchE and TRADE data demonstrates that abemaciclib dose modifications manage treatment-related adverse events without compromising efficacy in high-risk HR+, HER2− early breast cancer.

Treatment with ADCs for metastatic TNBC comes with a unique set of toxicities, and know how to manage, or adjust treatment as needed is important.

This descriptive systematic review of 14 studies found diagnostic delay in PABC was common and multifactorial, driven by both patient- and provider-related factors including symptom misattribution to pregnancy.

This phase 1/2 trial assessed HER2 BATs combined with pembrolizumab in metastatic breast cancer, finding the regimen safe and well tolerated with stable disease as the best response in 17 evaluable patients.

Panelists discussed 4 trials, which focused on 3 different ADCs and how each one is being utilized in their clinical practice.

This prospective, single-arm observational trial examines whether aromatase inhibitor therapy in postmenopausal women with HR-positive breast cancer adversely affects cardiorespiratory fitness, skeletal muscle function, and immunosenescence.

This randomized multicenter pilot trial assesses feasibility of the THRIVE Wellness Program, a 6-week lifestyle intervention for young breast cancer survivors aged 40 years or younger.

Survey of safety-net breast cancer patients links stronger faith to greater trust in doctors, especially among Black and lower-income groups.

Explore how breast cancer stem cell plasticity, epigenetic reprogramming, and single-cell insights drive therapy resistance, revealing new targets to improve durable responses.